Spots Global Cancer Trial Database for Intravitreal Injections of Melphalan for Retinoblastoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Intravitreal Injections of Melphalan for Retinoblastoma
Official Title: Intravitreal Injections of Melphalan for Retinoblastoma
Study ID: NCT01558960
Conditions
Interventions
Study Description
Brief Summary: Retinoblastoma treatment has become more and more focused in the last years. New treatments developed by Dr. Kaneko from Japan in 1995 are now being tested in clinical trials. Intra-arterial chemotherapy with Melphalan has shown success in some patients but with limited response when there is marked vitreal seeding. For these cases Intravitreal injections of Melphalan have been successful in Japan. In this study the same chemotherapy (melphalan) will be administered intravitreally (directly through the eye wall) and the response (short and long term) will be monitored.
Detailed Description: Intravitreal injections of Melphalan will be given to cases unresponsive to chemotherapy or with vitreal seeding of the disease.
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hadassah-Hebrew University Medical Center, Jerusalem, , Israel
Contact Details
Name: Shahar Frenkel, MD, PhD
Affiliation: Hadassah Medical Organization
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
